Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes
Year: 2014
Type: review
Abstract: The worldwide prevalence of obesity is steadily increasing, nearly doubling between 1980 and 2008. Obesity is often associated with insulin resistance, a major risk factor for type 2 diabetes mellitus (T2DM): a costly chronic disease and serious public health problem. The underlying cause of T2DM is a failure of the beta cells of the pancreas to continue to produce enough insulin to counteract insulin resistance. Most current T2DM therapeutics do not prevent continued loss of insulin secretion capacity, and those that do have the potential to preserve beta cell mass and function are not effective in all patients. Therefore, developing new methods for preventing and treating obesity and T2DM is very timely and of great significance. There is now considerable literature demonstrating a link between inhibitory guanine nucleotide-binding protein (G protein) and G protein-coupled receptor (GPCR) signaling in insulin-responsive tissues and the pathogenesis of obesity and T2DM. These studies are suggesting new and emerging therapeutic targets for these conditions. In this review, we will discuss inhibitory G proteins and GPCRs that have primary actions in the beta cell and other peripheral sites as therapeutic targets for obesity and T2DM, improving satiety, insulin resistance and/or beta cell biology. G proteins and their receptors provide potential drug targets for treating type 2 diabetes and obesity. In a review article, a team led by Michelle Kimple of the University of Wisconsin-Madison, USA, discusses the role of guanine nucleotide-binding proteins (G proteins) and G protein-coupled receptors (GPCRs) in the pancreatic beta-cell, which secretes insulin, and in other tissues that respond to insulin. The GPCRs are a large group of membrane proteins that respond to molecules outside the cell and activate responses inside the cell. The researchers highlight several specific GPCRs that animal or human studies have indicated might be particularly suitable as therapeutic targets for diabetes or obesity. These include the EP3 receptor, the α2A adrenergic receptor, the MT2 receptor and the CB1 receptor. Further research into these proteins may yield new therapies, conclude the authors.
DOI: 10.1038/emm.2014.40
Institutions: University of Wisconsin–Madison, Duke Medical Center
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $4,490
Awards: Molecular Mechanisms of Dysfunctional Prostaglandin Signaling in the Beta-Cell, Regulation of G-Protein Signaling, G3543016713, Role of G(alpha)Z in pancreatic islet beta-cell biology, G(alpha)Z signaling in insulin secretion and glucose tolerance, G9000300278, Biology of Aging and Age-Related Diseases
OpenAlex ID: W1967031212
